Open access · CC-BY
via OpenAlex
A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma
Rémy Nicolle, Odile Gayet, Pauline Duconseil, Charles Vanbrugghe, Julie Roques, Martin Bigonnet, Yuna Blum, Nabila Elarouci, Lucile Armenoult, Mira Ayadi, Aurélien de Reyniès, Francesco Puleo, Jérémy Augustin, Jean‐François Emile, Magali Svrcek
Annals of Oncology · 2020 · ▲ 105 citations
Abstract
BACKGROUND: Chemotherapy is the only systemic treatment approved for pancreatic ductal adenocarcinoma (PDAC), with a selection of regimens based on patients' performance status and expected efficacy. The establishment of a potent stratification associated with chemotherapeutic efficacy could potentially improve prognosis by tailoring treatments. PATIENTS AND METHODS: Concomitant chemosensitivity and genome-wide RNA profiles were carried out on preclinical models (primary cell cultures and patient-derived xenografts) derived from patients with PDAC included in the PaCaOmics program (NCT01692873). The RNA-based stratification was tested in a monocentric cohort and validated in a multicentric cohort, both retrospectively collected from resected PDAC samples (67 and 368 patients, respectively). Forty-three (65%) and 203 (55%) patients received adjuvant gemcitabine in the monocentric and the multicentric cohorts, respectively. The relationships between predicted gemcitabine sensitivity and patients' overall survival (OS) and disease-free survival were investigated. RESULTS: The GemPred RNA signature was derived from preclinical models, defining gemcitabine sensitive PDAC as GemPred+. Among the patients who received gemcitabine in the test and validation cohorts, the GemPred+ patients had a higher OS than GemPred- (P = 0.046 and P = 0.00216). In both cohorts, the GemPred stratification was not associated with OS among patients who did not receive gemcitabine. Among gemcitabine-treated patients, GemPred+ patients had significantly higher OS than the GemPred-: 91.3 months [95% confidence interval (CI): 61.2-not reached] versus 33 months (95% CI: 24-35.2); hazard ratio 0.403 (95% CI: 0.221-0.735, P = 0.00216). The interaction test for gemcitabine and GemPred+ stratification was significant (P = 0.0245). Multivariate analysis in the gemcitabine-treated population retained an independent predictive value. CONCLUSION: The RNA-based GemPred stratification predicts the benefit of adjuvant gemcitabine in PDAC patients.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1016/j.annonc.2020.10.601
- Canonical
- link ↗
- Fetched
- 2026-11-16 MST
Cite this
APA
Nicolle, R., Gayet, O., Duconseil, P., Vanbrugghe, C., Roques, J., Bigonnet, M., Blum, Y., Elarouci, N., Armenoult, L., Ayadi, M., Reyniès, A.D., Puleo, F., Augustin, J., Emile, J., Svrcek, M., Arsenijevic, T., Hammel, P.R., Giovannini, M.F., Grandval, P., & Dahan, L. (2020). A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma. <em>Annals of Oncology</em>. https://doi.org/10.1016/j.annonc.2020.10.601
Vancouver
Nicolle R, Gayet O, Duconseil P, Vanbrugghe C, Roques J, Bigonnet M, et al. A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma. Annals of Oncology. 2020. doi:10.1016/j.annonc.2020.10.601.
BibTeX
@article{rmy2020Atrans,
title = {A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma},
author = {Rémy Nicolle and Odile Gayet and Pauline Duconseil and Charles Vanbrugghe and Julie Roques and Martin Bigonnet and Yuna Blum and Nabila Elarouci and Lucile Armenoult and Mira Ayadi and Aurélien de Reyniès and Francesco Puleo and Jérémy Augustin and Jean‐François Emile and Magali Svrcek and Tatjana Arsenijevic and Pascal R. Hammel and Marc F. Giovannini and Philippe Grandval and Laëtitia Dahan and Vincent Moutardier and Marine Gilabert and Jean‐Luc Van Laethem and Jean‐Baptiste Bachet and Jerome F. Cros},
journal = {Annals of Oncology},
year = {2020},
doi = {10.1016/j.annonc.2020.10.601},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Gerontology 2018
Citation only
The Role of Frailty in Acute Coronary Syndromes in the Elderly
BMC Cancer 2018
Open access · CC-BY
Validation of a frailty index in older cancer patients with solid tumours
Journal of Clinical Oncology 2026
Citation only
Transcriptomic signature of temozolomide treatment-effect heterogeneity in IDH-wildtype glioblastoma.
American Journal of Respiratory and Critical Care Medicine 2007
Preprint · OA
Arterial Stiffness is Independently Associated with Emphysema Severity in Patients with Chronic Obstructive Pulmonary Disease
Journal of Cachexia Sarcopenia and Muscle 2023
Open access · CC-BY
Heterogeneity of weight loss and transcriptomic signatures in pancreatic ductal adenocarcinoma
AIDS 2023
Preprint · OA